📊 FNCH Key Takeaways
Is FNCH a Good Investment? Thesis Analysis
Finch Therapeutics is in severe financial distress with zero revenue, massive operating losses of $11.3M, and negative free cash flow of $9.1M despite holding $16M in cash. The company is burning through its cash reserves at an unsustainable rate with no demonstrated revenue-generating capability, and at current burn rates will exhaust its cash within approximately 1.8 years.
Why Buy FNCH? Key Strengths
- Strong liquidity position with $16M cash and 3.87x current ratio provides near-term runway
- No long-term debt eliminates financial distress risk from leverage
- EPS improved 35.4% YoY indicating reduced share dilution or loss reduction on per-share basis
FNCH Investment Risks to Consider
- Zero revenue with 87.6% YoY decline indicates failed commercialization or product-market fit issues
- Operating cash burn of $9.1M against $16M cash reserves indicates 1.8-year runway without revenue generation
- Negative ROE of -61.3% and ROA of -19.1% demonstrate severe value destruction for shareholders
- No insider buying activity in past 90 days suggests management lacks confidence in turnaround
- Biopharmaceutical company model typically requires multi-year development; inability to generate revenue after presumably reaching that stage is critical failure
Key Metrics to Watch
- Quarterly cash balance and burn rate trajectory
- Progress toward regulatory approval or commercial partnerships
- Operating cash flow trends and path to profitability timeline
FNCH Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.87x current ratio provides a solid financial cushion.
FNCH Profitability Ratios
FNCH vs Healthcare Sector
How Finch Therapeutics Group, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FNCH Overvalued or Undervalued?
Based on fundamental analysis, Finch Therapeutics Group, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FNCH Balance Sheet & Liquidity
FNCH 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Finch Therapeutics Group, Inc.'s revenue has declined by 95% over the 5-year period, indicating business contraction. The most recent EPS of $-72.12 indicates the company is currently unprofitable.
FNCH Growth Metrics (YoY)
FNCH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2024 | N/A | -$3.9M | $-3.01 |
| Q1 2024 | N/A | -$3.9M | $-2.41 |
| Q3 2023 | N/A | -$2.4M | $-1.51 |
| Q2 2023 | N/A | -$7.0M | $-4.33 |
| Q1 2023 | $107.0K | -$24.6M | $-0.52 |
| Q3 2022 | $138.0K | -$10.0M | $-0.21 |
| Q2 2022 | $361.0K | -$14.0M | N/A |
| Q1 2022 | $354.0K | -$14.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
FNCH Capital Allocation
FNCH SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Finch Therapeutics Group, Inc. (CIK: 0001733257)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FNCH
What is the AI rating for FNCH?
Finch Therapeutics Group, Inc. (FNCH) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are FNCH's key strengths?
Claude: Strong liquidity position with $16M cash and 3.87x current ratio provides near-term runway. No long-term debt eliminates financial distress risk from leverage.
What are the risks of investing in FNCH?
Claude: Zero revenue with 87.6% YoY decline indicates failed commercialization or product-market fit issues. Operating cash burn of $9.1M against $16M cash reserves indicates 1.8-year runway without revenue generation.
What is FNCH's revenue and growth?
Finch Therapeutics Group, Inc. reported revenue of $0.0.
Does FNCH pay dividends?
Finch Therapeutics Group, Inc. does not currently pay dividends.
Where can I find FNCH SEC filings?
Official SEC filings for Finch Therapeutics Group, Inc. (CIK: 0001733257) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FNCH's EPS?
Finch Therapeutics Group, Inc. has a diluted EPS of $-5.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is FNCH a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Finch Therapeutics Group, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is FNCH stock overvalued or undervalued?
Valuation metrics for FNCH: ROE of -61.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy FNCH stock in 2026?
Our dual AI analysis gives Finch Therapeutics Group, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FNCH's free cash flow?
Finch Therapeutics Group, Inc.'s operating cash flow is $-9.1M, with capital expenditures of $0.0.
How does FNCH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -61.3% (avg: 15%), current ratio 3.87 (avg: 2).